Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...
The logo of Bayer Mexico is pictured at the company's plant in Lerma, Mexico November 10, 2022. REUTERS/Henry Romero (Reuters) -The U.S. Food and Drug Administration has approved Bayer's drug to ease ...
On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with ...
The FDA approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. Obinutuzumab is just the third ...
The federal Food and Drug Administration today approved a new menopause drug that reduces hot flashes and night sweats after the drug was successfully tested at UVA Health and other sites in the ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...
Hosted on MSN
FDA approves drug for fatty liver diseaseDuring this National Liver Awareness Month, doctors are flagging an increase in fatty liver disease not related to alcohol use. Republicans push to overturn prop 4 with direct ballot initiative How a ...
Please provide your email address to receive an email when new articles are posted on . Editor’s note: This is a developing news story. Please check back soon for updates. The FDA approved ...
Another blood test will soon be available to help determine if someone has Alzheimer's disease. US Postal Service warning: Be alert for unexpected packages showing up on your doorstep Social Security, ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult ...
On Friday, the Food and Drug Administration announced a new pilot prioritization program for the review of abbreviated new drug applications that aims to spur and reward investment in U.S. drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results